MRES: M2Bio
Sciences Establishes Research Chair at The University of Pretoria
for Phytomedicines
CAPE TOWN, SOUTH AFRICA -- June
16, 2023 -- InvestorsHub NewsWire -- Institute of Biomedical
Research Corp. (OTC
PINK: MRES) ("Institute of Biomedical
Research" or the "Company"), a nutraceutical biotechnology company
focused on alternative plant-based cannabinoids, medical psilocybin
and mental health therapeutic research powered by artificial
intelligence, and evidence-based sustainable products and
solutions, is pleased to share the following update:
M2Bio Sciences is
delighted to announce it has signed an agreement with the
University of Pretoria/Universiteit van Pretoria
and
Enterprises University of Pretoria to continue
research into Plant Medicines, and the application of Artificial
Intelligence and Machine Learning to drug discovery and forensic
science.
The
agreement was cemented with the official signing ceremony on the
12th of May 2023 between Prof Barend Erasmus, Dean of the Faculty
of Natural and Agricultural Sciences, Mr. Jeff Robinson, CEO and
Chairman of M2Bio Sciences, and Dr. Elmar de Wet, CEO, Enterprises
University of Pretoria.
The UP
Biodiscovery Centre, led by
Prof Vinesh Maharaj, NAS
Deputy Dean for Research and Postgraduate Education and a renowned
bio-prospector, will conduct commercial natural product research
and development. The M2Bio Sciences Research Chair will conduct
research focused on science and evidence-backed premium health and
wellness products over the next four years.
An integral
part of the research is to use Artificial Intelligence (AI) to
discover natural product lead compounds that can be developed as
pharmaceutical and food ingredients.
"We need to emphasize the value of AI in African research. It is
important to digitize the great research and developments on the
continent. Although I am not a scientist, I have an enormous
passion for science, technology, and medicine and how they
intersect," Mr. Jeff
Robinson, CEO of M2Bio Sciences stated.
In
addition, Robinson believes very strongly that product development
must be backed by evidence-based scientific research.
"There is so much potential and talent in South Africa; I am
wondering why there are not more companies cooperating with
universities to do research," said Mr.
Robinson.
Prof Erasmus echoed
these sentiments, saying,
"There are three important elements of partnerships, especially
evident in today's agreement: the nature, aspirations, and the
vision of the people involved in this partnership. The three
partners, UP/NAS, M2Bio Sciences, and Enterprises UP, responded
well to this great opportunity. It is important to note that NAS
has many more unique value propositions as our diversity, ranging
from the basic sciences to the agricultural sciences, encompasses
the whole (agricultural) value chain."
Prof Maharaj added that
the partnership brings industry and academia closer and contributes
to creating a more significant impact on society through
translational and transdisciplinary research.
In his
final remarks, Mr. Robinson said that
"M2Bio Sciences is very excited to be working with Prof Maharaj
with his stellar knowledge – this translational research ties in
with the University's transdisciplinary research and is guided by
society's needs."
Dr. Elmar de Wet, CEO of UP
Enterprises, concluded the event by stating,
"The world has more than enough problems, and our scientists, in
partnership with industry, can facilitate the solutions and make it
happen."
"Much more detail on this agreement and the current research on the
go will be released very soon.
Stay tuned and keep connecting the dots!" said
Robinson.
About Institute of
Biomedical Research Corp./ DBA M2Bio Sciences
Institute of Biomedical Research
Corp, is a nutraceutical biotechnology company focused on
alternative plant-based cannabinoids, medical psilocybin and mental
health therapeutic research powered by artificial intelligence, and
evidence-based sustainable products and solutions, that develops
and commercializes a range of CBD and mushrooms-based products
under Dr. AnnaRx™, Medspresso™, Liviana™ brands as well as
artificial intelligence powered nutrition products and solutions
under the M2Biome brand. In addition, our research and clinical
trials with psilocybin are aimed at new therapies that will help
patients who suffer from alcohol addiction, mental illness, and
cardiovascular diseases. Our mission is to advance botanical-based
medicine to the forefront by deploying best-practice science and
medicine, clinical research, and emerging technologies such as
artificial intelligence. The Company is traded on the
Over-the-Counter Bulletin Board of NASDAQ under the trading symbol
"MRES".
Publicly traded Company (OTC
Pink: MRES)
www.m2bio.co
jeff@m2bio.co
+27 72 333 2148
Find M2Bio™ on
social media
Facebook:
M2Bio
Instagram:
M2bio.Sciences
LinkedIn:
M2Bio
Twitter:
@M2bio
Forward-Looking
Statements
Safe Harbour
Statement - In addition to historical information, this press
release may contain statements that constitute forward-looking
statements within the meaning of the Securities Act of 1933 and the
Securities Exchange Act of 1934, as amended by the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements contained in this press release include the intent,
belief, or expectations of the Company and members of its
management team with respect to the Company's future business
operations and the assumptions upon which such statements are
based. Prospective investors are cautioned that any such
forward-looking statements are not guarantees of future
performance, involve risks and uncertainties and that actual
results may differ materially from those contemplated by such
forward-looking statements. Factors that could cause these
differences to include, but are not limited to, failure to complete
anticipated sales under negotiations, lack of revenue growth,
client discontinuances, failure to realize improvements in
performance, efficiency, and profitability, and adverse
developments with respect to litigation or increased litigation
costs, the operation or performance of the Company's business units
or the market price of its common stock. Additional factors that
could cause actual results to differ materially from those
contemplated within this press release can also be found on the
Company's website. The Company disclaims any responsibility to
update any forward-looking statements. $mres